The quality of data comparing care at the end of life (eol) in cancer patients across Canada is poor.
INTRODUCTION
Palliative care plays an important role on the cancer care continuum. In particular, it aims to enhance quality of life at the end of life (eol) 1 . Without effective health care interventions, many cancer patients have uncontrolled symptoms, poor quality of life, and unnecessary suffering [2] [3] [4] [5] [6] [7] [8] [9] . The literature suggests that, over time, cancer care is becoming more aggressive near the eol 10, 11 . The literature also suggests the presence of a discrepancy between what patients report as their preferred place of death (most often home) and their actual place of death [12] [13] [14] [15] [16] [17] [18] [19] [20] . Compared with people receiving patient-centred palliative care services at home, those who die in institutions such as acute care facilities have unmet needs for symptom control, physician communication, emotional support, and respectful treatment 21, 22 .
The use of administrative health care data to evaluate quality indicators of eol care was originally developed in the United States through a combination of literature review, lay focus groups, and expert panels 23 . A similar panel of indicators has been developed for the Canadian setting 24 . An aggregate score of "aggressive care" has been described in both the United States and Canada 10, 11 . Knowing which services patients receive before death offers insight into whether they are accessing resources meant to improve quality of death and dying 25 .
Since the early 2000s, the quality of eol care in Canada has been highly criticized in a series of federal and provincial reports [26] [27] [28] [29] [30] [31] [32] . Those criticisms have included lack of expertise and of adequate home support services, lack of coordinated comprehensive programs, fragmentation of care, and inadequate caregiver support. Although eol care has been studied in several provinces 14, 22, [33] [34] [35] [36] [37] [38] [39] , the quality of data for comparing eol care in cancer patients across Canada is poor.
In 2010, the Canadian Cancer Society reported on eol care as a special topic for their annual report. The authors concluded that comparisons between provinces are limited because of a lack of standard definitions and methods, and an inability to link data across provinces 40 . Ironically, more high-quality research has been published comparing eol care in Ontario and the United States than between provinces in Canada 11, 41 . The purpose of the present project was to evaluate eol quality indicators in cancer patients from British Columbia, Alberta, Ontario, and Nova Scotia.
METHODS

Study Design
This retrospective cohort study considered patients with a confirmed cancer cause of death between 1 April 2004 and 31 March 2009 in four Canadian provinces: British Columbia, Alberta, Ontario, and Nova Scotia. Patients less than 19 years of age at the time of death and those with an invalid provincial health card number were excluded.
Data Sources
Index cases of death from cancer were identified from the cancer registries of each participating province. All registries are population-based and capture at least 90% of all incident cancer cases [42] [43] [44] [45] . Encoded unique health card numbers were used to link cases to administrative health databases within each province so as to obtain information about health services received at eol. Data were not merged across provinces, but were analyzed independently.
The source databases included the Discharge Abstract Database maintained by the Canadian Institute for Health Information 46, 47 , which contains diagnostic and procedure information about all acute care hospitalizations in Canada; the National Ambulatory Care Reporting System 48 , which, for Alberta and Ontario, contains information from hospital and community-based ambulatory care including day surgeries, outpatient clinics, and emergency departments (eds); physician billing claims databases from provincial health insurance plans (the Medical Services Plan in British Columbia 49 , Medical Services Insurance in Nova Scotia, and the Ontario Health Insurance Plan in Ontario), which provide information on reimbursement claims made by physicians for services provided to patients; databases available from provincial organizations overseeing home care services (Home and Community Care in British Columbia 50 , Continuing Care in Nova Scotia, and the Ontario Association of Community Care Access Centres in Ontario); and the BC Cancer Agency's Systemic Therapy database for chemotherapy treatment information. Physician claims and home care data were not available for Alberta, and chemotherapy data were not complete for Nova Scotia.
Sociodemographic information was obtained from the cancer registries of all provinces except Ontario and British Columbia, where public health insurance registration records were used 51, 52 . The Statistics Canada 2006 census profile was used to obtain neighbourhood income and community size information. Additionally, as a measure of baseline comorbidity, a Charlson-Deyo modified score was calculated using hospitalizations in the 6 months before death 53 . The score is calculated by summing the points for a predefined list of conditions, with the points for cancer excluded.
Health Service Quality Indicators
We examined health service quality indicators commonly used and previously identified as important to quality care at eol 23, 24 , where eol is considered to be the time shortly before death. Indicators for which higher use is considered lower quality include ed use in both the last 2 weeks and the last 30 days of life, a new hospital admission in the last 30 days of life, intensive care unit (icu) admission in the last 30 days of life, chemotherapy use in the last 2 weeks of life, and death in an acute care hospital. Indicators for which higher use is considered higher quality include physician house calls in the last 2 weeks of life, and nursing and personal support worker visits at home in the 6 months before death. Because the icu admission date for one province was unknown, admissions to the icu were counted only if the hospital admission date was within 30 days of death. Because patients considered palliative are eligible for increased home care services, we also examined a separate indicator for palliative home care, defined as receiving a nursing or personal support worker visit at home in the 6 months before death, with a specific flag or indicator of the palliative intent of the care.
Aggregate measures of aggressive and supportive care combining selected indicators were also developed:
n "Aggressive care" was defined as any one or a combination of ed visits (2 or more), a hospitalization, or an icu admission in last 30 days of life 10, 11 . Although the earlier literature included chemotherapy use in the aggressive care measures, variation in the sources of chemotherapy data between the provinces studied here would limit their comparability, and thus chemotherapy was excluded. n "Supportive care" was defined as either or both of a physician house call in the 2 weeks before death and a palliative nursing or personal support worker visit at home (as already defined) in the 6 months before death. That aggregate measure was created specifically for the present study. 
Statistical Analysis
Baseline characteristics of each provincial study population were compared using descriptive statistics. Crude For each province, two separate multivariable logistic regression models were used to examine factors associated with receipt of aggressive and supportive care. Factors included in the adjusted models were age, sex, score on the Charlson-Deyo comorbidity index 53 , cancer type, neighbourhood income quintile, community size, health service region, and fiscal year of death. Age was included in the model as a continuous variable. The remaining variables were categorical. Each province was checked for colinearity between community size and region using the variance inflation factor. No colinearity was found, and so both variables were included in the model. Odds ratios (ors) are reported with 95% confidence intervals (cis) and are considered statistically significant if the confidence interval does not include 1.00.
Because nursing and personal support worker home visits and physician house call data were not available from Alberta, analyses of those indicators and of supportive care were not performed for that province. Statistical analyses were performed using the SAS (version 9. 
RESULTS
During the study period, 200,285 patients in the four provincial cancer registries who died from their cancer met the eligibility criteria for inclusion in the study (Table ii) . Overall, mean age at death was 71.4 ± 12.9 years, and 47% were women. Demographics were similar across the provinces. Compared with the other provinces, British Columbia had a slightly lower proportion of cases with a score of least 1 on the Charlson-Deyo comorbidity index, and the Nova Scotia study population lived in smallersized communities. Table iii shows the crude and standardized quality indicator rates by province, for all years combined. Overall, 54% of patients died in a hospital, with British Columbia having the lowest standardized rate of such deaths at 50.2%. Patients hospitalized within 30 days of death varied from 49.2% in Nova Scotia to 60.7% in Ontario. Rates of admission to the icu were similar. Comparing ed visit data from the Discharge Abstract Database (ed visits captured from hospital admissions via the ed), Nova Scotia also had the lowest use of ed within both 2 weeks and 30 days of death (22.2% and 30.7% respectively); Ontario had the highest use (35.7% and 47.9%). Rates estimated using the National Ambulatory Care Reporting System and physicians claim data in Alberta and Ontario were 4%-10% higher than the rates estimated using hospitalization data, but relative use across provinces was unchanged. In Nova Scotia, rates estimated using claims were lower. Intravenous chemotherapy treatment in the last 2 weeks of life ranged from 2.4% in Alberta to 4.8% in British Columbia; however, this particular comparison must be interpreted with caution because of the varying types of data sources used to gather the information. Nova Scotia chemotherapy data were incomplete.
With respect to the aggregate indicators, 8.7% of all patients received aggressive care, with rates being similar in all provinces. Supportive care was received by 46.3% of the study population. The highest rate of supportive care was observed in British Columbia (61.8%), and the lowest, in Nova Scotia (41.2%). Results across years were relatively stable.
In regression analyses, younger age, male sex, and residence in smaller-sized communities were all associated with an increased likelihood of receiving aggressive care (Table iv) , an observation that was consistent for all provinces. In Ontario, living in a low-income neighbourhood or having a score of 1 or more on the Charlson-Deyo comorbidity index were also associated with receipt of aggressive care. Factors associated with an increased likelihood of supportive care receipt were younger age, female sex, no comorbidity, lung cancer, living in a higher-income neighbourhood and in a larger community, although some exceptions were observed (Table v) . Notably, compared with people in the highest-income neighbourhoods, people living in the lowest-income neighbourhoods had a 0.73-0.87 likelihood of receiving supportive care.
DISCUSSION
We successfully used administrative health care data to create identically defined cohorts with commonly defined indicators in four Canadian provinces that include about 65% of the Canadian population. Moderate differences in the indicators were observed between provinces, but overall, more than half the cancer patients died in hospital and 2 in 5 visited the ed near the eol. Associations with explanatory covariates were similar in all the provinces, suggesting that observations from a single province are generalizable to others. One of the strongest associations observed was that patients living in poorer neighbourhoods were less likely to receive supportive care services.
The present work makes an important contribution to maturing the study of eol cancer care in Canada. It addresses some of the gaps previously identified by the Canadian Cancer Society-specifically, comparing identically defined cohorts during the same years, with indicators defined as identically as the data allow. This work is in keeping with priorities outlined by the U.S. Institute of Medicine's recent report 54 , such as providing patients and families with eol care that consistent with their values and developing a national quality reporting program. 
Strengths and Limitations
Our study has several strengths. Its population-based cohorts of cancer decedents were identified using a common method, and it examines care provided in the inpatient, ambulatory, and community settings. Earlier work was conducted primarily within single provinces 14, [33] [34] [35] [36] [37] [38] [39] . The provincial populations included in the present study account for more than half the Canadian population. Tremendous effort was taken to ensure that the indicators represent fair comparisons, despite the variety of data sources. The Canadian Partnership Against Cancer is monitoring location of death across the country, but that variable is reported as an unadjusted value 55 . Interpretation is further limited because location of death is identified from the death certificate, and there are differences in death certificate reporting. The Canadian Institute for Health Information has released a national-level report on eol care, but its study included only patients who died in hospital and was able to examine only care delivered in an inpatient setting, thus excluding care delivered in the community 56 .
There are limitations to the present study. All of the methodology choices made prioritized assurance of an "apples to apples" comparison. In some cases, options were limited. For example, ed visits were not available for all provinces from either the National Ambulatory Care Reporting System (a data source that specifically captures ed visits) or physician claims data. For that reason, inpatient hospitalization data were used to identify patients admitted to hospital via the ed. As a result, ed visits that did not lead to hospitalization were not counted. In other cases, the data required to evaluate an indicator could not be obtained. For example, the custodians of home care data in Alberta did not release it for inclusion in the study. Although cause-of-death data are available for more recent years from some provinces, the availability of such 
Comparison with Other Studies
The indicator values and associations reported here are in keeping with earlier Canadian results 24, 33 . Notably, in all provinces studied, patients living in lower-income neighbourhoods were less likely to receive supportive care and, in Ontario, were more likely to receive aggressive care. In all provinces, people residing in smaller communities were more likely to receive aggressive care and less likely to receive supportive care. In contrast to earlier work using data from the early 2000s, an increase in aggressive care over time was not evident 11 . That discrepancy might be a result of our inability to include chemotherapy in the aggregate indicator of aggressive care, although the earlier work indicated that all types of aggressive care increased over time. Alternatively, aggressive eol care might be beginning to stabilize. Other countries have reported similar data. For example, Canadian in-hospital death rates seem to be higher than those in the United States, but similar to those in Taiwan 41, 57, 58 .
CONCLUSIONS
We successfully used administrative health care data to create identically defined cohorts with commonly defined indicators for four Canadian provinces. National reporting of quality of care improves the contextual understanding of variations in care. It facilitates a richer consideration of differences in the structures and processes of care that might contribute to the variations. The time and effort Chemotherapy within 2 weeks of death Toronto Central 1.00 --required to produce these results was, however, tremendous and raises feasibility issues with respect to ongoing surveillance in the absence of a more integrated national data platform. Future work in this arena would be facilitated by data-sharing arrangements at the national level. 
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